BofA downgraded Zai Lab (ZLAB) to Neutral from Buy with a price target of $36.10, up from $29. The firm cites the growth slowdown of the company’s core products and its belief that Zai’s near-term positive news has been priced into the shares for the downgrade. The company reported in-line 2024 results with “soft” sales of Zejula and Optune, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB: